Laser balloon angioplasty: potential for reduction of the thrombogenicity of the injured arterial wall and for local application of bioprotective materials.
Mitigation of adverse biologic reactivity after balloon angioplasty is necessary before the incidence of restenosis can be appreciably reduced. A brief review of experimental evidence supports the hypothesis that the thrombogenicity of the injured arterial wall can be reduced by a suitable level of thermal denaturation or cross-linking of thrombogenic proteins. In addition, the concept of local pharmacologic therapy, which can be provided with laser balloon angioplasty at the site of arterial injury, is introduced. Preliminary in vitro and in vivo data suggest that guide catheter-injected albumin-heparin conjugates fabricated as water-insoluble microspheres remain adherent to the injured luminal surface and deeper arterial layers after physical trapping by the inflated balloon and subsequent laser/thermal exposure. The combination of initially adequate luminal morphology, reduction of the thrombogenicity of the injured arterial wall and application of local pharmacologic therapy with laser balloon angioplasty may eventually prove helpful in reducing the incidence of restenosis.
Spears
J R
JR
Department of Medicine, Harper Hospital/Wayne State University, Detroit, Michigan.
Kundu
S K
SK
McMath
L P
LP
D016342:Angioplasty, Laser / Q000379:methods; D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000187:drug effects / Q000601:surgery; D004285:Dogs; D004337:Drug Carriers; D006493:Heparin / Q000008:administration & dosage; D006629:Hirudins / Q000008:administration & dosage; D008863:Microspheres; D012008:Recurrence; D012709:Serum Albumin / Q000008:administration & dosage
D001672:Biocompatible Materials; D004337:Drug Carriers; D006629:Hirudins; D012709:Serum Albumin; D006493:Heparin